智通财经APP讯，维康药业(300878.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的黄甲软肝颗粒的《药物临床试验补充申请批准通知书》，经审查，黄甲软肝颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于慢性乙型病毒性肝炎肝纤维化的III期临床试验。
智通财经APP讯，维康药业(300878.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的黄甲软肝颗粒的《药物临床试验补充申请批准通知书》，经审查，黄甲软肝颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于慢性乙型病毒性肝炎肝纤维化的III期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.